Medytox In China JV Deal, Aims To Set Up More Asian Units
This article was originally published in PharmAsia News
Executive Summary
After the establishment of its first overseas subsidiary in Taiwan early this year, Medytox has set up a joint venture with China's Bloomage BioTechnology to sell its botulinum toxin products and hyaluronic acid fillers in China. The South Korean biopharma company is aiming to establish more subsidiaries in other major Asian countries as part of plans to directly sell its products in the region.
You may also be interested in...
SK Bioscience First To Line In Korea COVID Vaccine Race
SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.
Korea’s First Home-Grown COVID-19 Vaccine To Speed Hub Ambitions
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.
China Rush Over? Korean Firms Step Up To Seize Opportunities
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.